Leading the Charge in Autoimmune Innovation

Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi®️ (tafasitamab), and advanced the company’s pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys’ position in oncology innovation and ultimately leading to its subsequent acquisition by Novartis in 2024. Prior to that, he was CEO of Syntimmune, guiding its lead immunology program through to acquisition by Alexion Pharmaceuticals. He currently serves on the Board of Sanofi S.A. and has held senior roles across leading biopharma companies. Dr. Kress holds graduate and post-graduate degrees in biochemistry and molecular and cellular pharmacology from Ecole normale superieure, Paris, and an M.D. from Faculte Necker-Enfants Malades, Paris.

Mr. Mahatme joins Vor Bio with more than 30 years of executive leadership experience in the biopharmaceutical industry, with a strong track record in capital markets, business development, global operations, and shareholder value creation. He most recently served as President, Chief Operating Officer, and Chief Financial Officer of National Resilience, Inc., a biomanufacturing company he co-founded in 2020. During his tenure, he raised over $2.5 billion in equity and non-dilutive capital.

Prior to Resilience, Mr. Mahatme served as Executive Vice President, Chief Financial Officer and Chief Business Officer of Sarepta Therapeutics, where he led capital formation efforts exceeding $3.5 billion and built the company’s pipeline through a series of strategic licenses, collaborations, and acquisitions. He also served as Senior Vice President, Corporate Development and Corporate Treasurer and Senior Vice President, Tax at Celgene Corporation. Mr. Mahatme currently serves on the boards of CRISPR Therapeutics and Idorsia Pharmaceuticals. He holds Master of Laws degrees from Cornell Law School and New York University School of Law and is a member of the New York Bar.

Dr. Sokolove brings more than 18 years of experience leading clinical development and translational research in autoimmune and inflammatory diseases across biotechnology and pharmaceutical organizations.

Prior to joining Vor Bio, Dr. Sokolove was Chief Medical Officer In-Residence at Roivant Sciences, where he led strategic assessment and in-licensing of novel therapeutic programs and provided clinical and operational leadership across Roivant’s portfolio companies. Previously, he served as Chief Medical Officer at Odyssey Therapeutics, guiding the company’s transition to a clinical-stage organization developing next-generation immunomodulators for autoimmune and inflammatory diseases.

Earlier in his career, Dr. Sokolove held senior leadership positions at GlaxoSmithKline as Senior Vice President and Head of Clinical Pharmacology & Experimental Medicine, and at AbbVie as Head of Immunology Translational Science, where he established portfolio-wide translation strategies, led registrational studies of upadacitinib (RINVOQ) in rheumatoid arthritis and giant cell arteritis, as well as Phase 2 combination studies of a novel JAK/BTK combination in rheumatoid arthritis and lupus.

An accomplished physician-scientist and rheumatologist, Dr. Sokolove was previously on the faculty at Stanford University Medical Center, has authored more than 90 peer-reviewed publications, and has served on editorial boards of leading medical journals.

Dr. Sokolove earned his MD from Boston University School of Medicine and completed his Internal Medicine residency at Boston University Medical Center, where he served as Chief Medical Resident. He completed clinical and research fellowships in Rheumatology and Immunology at Stanford University.

Dr. Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she was one of the key leaders of successful development and execution of clinical trials for telitacicept across four key indications, systemic lupus erythematosus (SLE), Sjögren’s syndrome, myasthenia gravis (MG), and rheumatoid arthritis (RA), culminating in regulatory approvals in China for the treatment of SLE, generalized MG and RA.

Dr. Zuraw has also previously held senior leadership roles at Janssen Research & Development, Teva Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Biogen Inc., and Covance, Inc., where she led global clinical development programs across rheumatology, nephrology, respiratory, and immunology.

Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies.

He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In that role, he led the commercial and medical affairs organizations, along with the international business unit. Under his leadership, Sarepta achieved approximately $1.8 billion in net product revenue in 2024. While at Sarepta he oversaw multiple product launches, including the launch of the first RNA therapy and first gene therapy for duchenne muscular dystrophy.

Over the course of his career, Mr. Murray has led or supported more than a dozen product launches, including INCIVEK at Vertex Pharmaceutics, Inc., the fastest launch to $1 billion in biotech history at the time, and multiple global rollouts at Gilead Sciences, Inc., Biogen Inc., and Johnson & Johnson.

Mr. Murray holds an MBA from Queen’s University in Ontario, Canada, and a Bachelor of Commerce from the University of Alberta.

Dr. Osovsky brings nearly two decades of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. She joins Vor Bio from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal & Corporate Secretary. In that role, she led the company’s corporate legal and compliance activities and oversaw information technology.

She previously held senior legal roles at Sarepta Therapeutics, supporting corporate transactions, securities matters, and governance through a period of rapid growth and transformation.

Dr. Osovsky holds an LL.B. from Tel Aviv University and both an LL.M. and an S.J.D. in Securities Regulation from Harvard Law School.

Carol Lincoln brings more than 25 years of experience leading human resources strategy, total rewards, and operations across the biotechnology, pharmaceutical, financial services, and publishing industries.

She joins Vor Bio from iTeos Therapeutics, where she most recently served as Head of Total Rewards and U.S. Human Resources. In that role, she led the creation and build-out of the company’s U.S. HR function, establishing foundational people processes, policies, and compliance frameworks, and built and implemented global compensation and benefits programs to support the company’s expanding immuno-oncology portfolio and growing international footprint.

Prior to iTeos, Carol served as Director of Total Rewards at Finch Therapeutics and Director of Total Rewards and Operations at Cyclerion Therapeutics, where she helped establish Human Resources infrastructure following its spin-out from Ironwood Pharmaceuticals. Earlier in her career, she was with Ironwood Pharmaceuticals, where she held a series of leadership roles spanning Human Resource operations, HRIS, and benefits administration during a period of rapid growth and multiple product launches.

Carol holds a B.A. in English from the University of Massachusetts Amherst and is a Certified Compensation Professional (CCP).